Join
Live feed
·
PRReleasevia Quantisnow
Serina Therapeutics Inc. logo

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

ByQuantisnow·Wall Street's wire, on your screen.
SER· Serina Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SER (Serina Therapeutics Inc.) and more on Quantisnow.